Study of the Immunological Pathophysiological Mechanisms Associated With Acute Respiratory Distress Syndrome

About 10% of patients admitted to the ICU suffer from ARDS, with a mortality rate of around 35-45%. The lack of therapeutic innovation in ARDS can be partly explained by the heterogeneity of patients included under this definition. A better understanding of the pathophysiological mechanisms underlying the different patient phenotypes is essential to develop new therapeutic strategies. Objectives: To characterize the inflammatory profile of patients with ARDS using circulating biomarkers and single-cell RNA sequencing of pulmonary immune cells. The investigators hypothesize that there is a correlation between the profile of serum biomarkers (inflammatory sub-phenotypes), the transcriptome of pulmonary immune cells. Briefly the experimental scheme is as follow: * Population: patients with ARDS under invasive mechanical ventilation in the ICU. * Intervention: 1. Determination of the inflammatory subphenotype on circulatory inflammatory biomarkers. 2. Characterization of inflammation by single cell RNA sequencing on lung immune cells collected on broncho-alveolar fluid.

NCT Number	NCT07395076
Lead Sponsor	Assistance Publique - Hôpitaux de Paris
Conditions	Acute Respiratory Distress Syndrome (ARDS)
Enrollment	50 participants
Start Date	2026-05-11
Primary Completion	2029-05-11 (estimated)
Study Completion	2029-05-11 (estimated)
Updated on ClinicalTrials.gov	2026-05-14